Author Archives: admin


Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as…

PUNE, India, Jan. 8, 2020 /PRNewswire/ -- In terms of revenue, global gene therapy market was valued at US$ 919.6 million in 2018 and is anticipated to reach US$ 5,609.9 million by 2027, growing at a CAGR of 8.2% over the forecast period. Market participants are adopting partnerships or acquisition as their strategy to strengthen their foothold. For instance, Pfizer Inc. acquired Medivation, Inc. and Bamboo Therapeutics, Inc. to develop a focused product for the treatment of patients with rare diseases related to neuromuscular and central nervous system. Companies are building relationships with community and patients to understand the disease and design therapies accordingly.

Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=308

Lethal diseases like cancer can be treated using gene therapy by inserting the antisense strands to revert the effect of the oncogenes using bio engineered vectors. Recently, scientists developed bionic chip to transfer DNA to cells using electroporation technique. During the forecast period, nanoparticles will play an important role in gene delivery systems to increase the efficiency of transfection of the non-viral carriers, thereby, fuelling the gene therapy market.

Due to drastic shift in treatment patterns, gene therapy treatment is considered one of the reliable cures for lethal diseases. The vectors or the DNA carriers are safer and have improved in terms of carrying genes without rejection which help the companies to attract venture capitalists to invest more in gene therapy market. Most of the research companies are focusing on development of gene carriers for the successful gene delivery. One of the prominent used vectors among the gene vehicle family is adeno associated virus. Cancer and Sensory disorders are the major area of concern that need to be fixed and hence drug development related to these disease is driving the gene therapy market.

Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=308

The detailed research study provides qualitative and quantitative analysis of gene therapy market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Key Findings of the Report:

Request for Customization@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=308

Gene Therapy Market

By Geography

For More Information Visit@ https://www.absolutemarketsinsights.com/reports/Gene-Therapy-Market-2019-2027-308

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:Company:Absolute Markets InsightsEmail id:sales@absolutemarketsinsights.comPhone:+91-740-024-2424Contact Name:Shreyas TannaThe Work Lab, Model Colony, Shivajinagar, Pune, MH, 411016Website:https://www.absolutemarketsinsights.com/

SOURCE Absolute Markets Insights

The rest is here:
Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as...

CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis – Associated Press

MENLO PARK, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today announced the discovery of a series of novel mitochondrial peptide analogs with potent in vitro activity as selective inhibitors of C-X-C Chemokine Receptor Type 4 (CXCR4) and with preliminary in vivo efficacy in a mouse model of melanoma, including substantial reduction in tumor growth as compared to control animals. CXCR4 is a key regulatory receptor involved in tumor growth, invasion, angiogenesis, metastasis, and resistance to therapy.

This new discovery offers the potential to develop novel therapeutics for difficult-to-treat cancers, based on peptides encoded in the mitochondrial genome, said Ken Cundy, Ph.D., CohBars Chief Scientific Officer. Inhibition of this key regulatory pathway is potentially applicable to a wide range of cancers, as well as orphan indications where CXCR4 signaling is dysregulated.

Novel peptide analogs of a mitochondrially encoded peptide (MBT5) demonstrated potent and selective inhibition of human CXCR4 receptor in cell-based assays, with IC50 values in the low nanomolar concentration range. In a difficult-to-treat in vivo mouse model of melanoma, the B16F10 syngeneic tumor model, the combination of an analog of MBT5 administered subcutaneously with the chemotherapeutic temozolomide showed enhanced antitumor activity, reducing tumor growth after 11 days by 61% compared to control animals. The reduction in tumor growth produced by the combination exceeded the effect of either temozolomide used as a single agent, which reduced tumor growth by 38% compared to control, or the murine checkpoint inhibitor anti-PD-1 antibody, which had no effect on tumor growth in this model.

CohBar plans to further explore the efficacy of this new family of peptides in additional animal models with the goal of identifying a new clinical development MBT candidate.

These new data further expand our understanding of the broad regulatory influence exerted by mitochondria and the therapeutic potential of analogs of peptides encoded in mitochondrial DNA, said Steve Engle, CohBar CEO. We are just beginning to scratch the surface of this previously untapped field.

CXCR4 is overexpressed in more than 75% of cancers and high levels of the receptor are associated with poor survival prognosis. Inhibition of the CXCR4 receptor has been shown to mobilize immune cells, enhance the effects of chemotherapy and immunotherapy in various cancers, and reduce the development of metastatic tumors by blocking the ability of tumor cells to evade immune surveillance. CXCR4 also regulates the homing and retention of hematopoietic stem cells and malignant cells in the bone marrow.

Further details of these new studies will be available on the CohBar website at http://www.cohbar.com.

About CohBar

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBars founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial-derived peptides. CohBars efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, type 2 diabetes, and cardiovascular and neurodegenerative diseases. The companys lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial that includes an evaluation of biological activity relevant to NASH and obesity.

For additional company information, please visit http://www.cohbar.com.

Forward-Looking Statements

This news release contains forward-looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as believe, may, will, estimate, continue, anticipate, intend, could, should, would, project, plan, expect, goal, seek, future, likely or the negative or plural of these words or similar expressions. Examples of such forward-looking statements including but not limited to statements regarding the ability of mitochondrial peptide analogs to reduce tumor growth in mice; anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs and MBTs. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable than and that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; and our ability to establish and maintain partnerships with corporate and industry partners. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at http://www.sec.gov or http://www.sedar.com.

You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

Investor and Media Contact:Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650) 445-4441 Jordyn.tarazi@cohbar.com

Joyce AllaireLifeSci Advisors, LLC jallaire@lifesciadvisors.com

Continued here:
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis - Associated Press

Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing – Yahoo…

ROCKVILLE, Md., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company developing a comprehensive platform of chimeric antigen receptor (CAR) T cell therapies for liquid and solid tumors,today announced the appointment of Christopher Ballas, Ph.D., as Senior Vice President of Manufacturing. Dr. Ballas previously served in senior manufacturing roles at Rocket Pharmaceuticals and WuXi AppTec, with a focus on gene and cell-based therapies.

Our need for quality vector and cell production is growing as we advance our liquid and solid tumor CAR-T programs into the clinic in the United States. We intend to assume full control of our key manufacturing processes, said Larry (Lei) Xiao, Ph.D., ICTs Founder and Chief Executive Officer. Chris is a valued addition to the ICT management team, as he will lead our manufacturing efforts and the expansion of our related infrastructure, Dr. Xiao added.

Dr. Ballas brings more than 20 years experience of working on cell and gene therapies. Most recently, he served as Vice President of Manufacturing for Rocket Pharmaceuticals, a leading publicly traded U.S. gene therapy company. Previously, he served as Senior Director of Process Development and Commercialization for WuXi AppTec, where he was responsible for manufacturing operations and program management for gene therapy clients. Dr. Ballas oversaw key programs including CAR-T, TIL, and classic CD34+ stem cell gene therapy.

Prior to WuXi AppTec, Dr. Ballas ran autologous cell therapy clinical trials for Cook Medical. Dr. Ballas also held several roles at the Indiana University School of Medicine, where he developed the initial, scalable, clinical production capabilities for lentiviral vectors at the IU Vector Production Facility. As a faculty member, Dr. Ballas developed his own research programs targeting stem cells for gene therapy, which resulted in the collaborative development of an ultra-high throughput microinjection device with colleagues at the University of California Riverside (US9885059). In the past, Dr. Ballas served as an expert consultant to numerous companies on gene therapy and the production and use of viral vectors for gene therapies with contributions to Chemistry, Manufacturing and Control (CMC), regulatory filings, and regulatory meetings.

Dr. Ballas has a Ph.D. in Cellular and Molecular Pathology from the Vanderbilt University School of Medicine and was a Childrens Brittle Bone Foundation fellow during his post-doctoral fellowship at Case Western Reserve University School of Medicine.

Dr. Ballas said, I have a passion for solving the practical challenges associated with producing and using viral vectors to deliver genes and create differentiated therapies. ICTs CAR-T platform is unique and compelling, and I look forward to leveraging my experience to optimize and expand our manufacturing capability to produce world-class products with the potential to transform cancer immunotherapy.

About Innovative Cellular TherapeuticsInnovative Cellular Therapeutics (ICT) is a clinical stage biotechnology company focused on the development of cellular immunotherapies for the treatment of liquid and solid tumors. ICT has achieved promising preclinical and clinical results in late-stage leukemia and lymphoma with its next generation CAR-T constructs. ICTs lead candidate in the United States, ICTCAR014, is a next generation CD19-targeting ArmoredCARTM T cell therapy that expresses a dominant negative PD-1 (dnPD-1) protein to block immunosuppression by cancer cells. ICTCAR014 has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application clearance and is being developed for patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including PD-L1 positive patients. In solid tumor, ICT has compelling human data from IRB-approved proof-of-concept trials in China demonstrating the viability of its proprietary CoupledCARTM technology platform. For more information, please visitwww.ictbio.com.

Read more here:
Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - Yahoo...

Kevin Nash on How His Health Is After Knee Replacement & Stem Cell Therapy, Why He Retired – LordsofPain.net

WWE Hall of Famer Kevin Nash took to Twitter this week with several tweets on his health.

Nash made a tweet on Monday and apparently responded to a recent report or quote on his retirement status. The former WWE Champion said hes in the best physical shape as far as function hes been in since 1986.

How after wrestling once in 2 years as a favor is it news Im retired? I had a knee replacement and stem cell therapy to heal my wounds. Now Im in the best physical shape as far as function than Ive been since 1986 when I destroyed my right knee. I worked 29 years on one leg, Nash tweeted.

Nash made another tweet on Tuesday and included photos to show off the impressive physical shape that he is in at 60 years old. He commented on the knee replacement and two years of rehab & training hes went through.

The reason I retired was I was deformed and basically crippled, Nash revealed. This knee replacement and 2 years of rehab and training has been brutal. Just get my hips to realign was incredibly painful. To the haters fuck off To those that have championed my recovery I send my thanks and love.

Nash is set to become a two-time WWE Hall of Famer during WrestleMania 36 weekend in Tampa later this year as the nWo is inducted as a group (Nash, Hulk Hogan, Scott Hall, Sean Waltman).

You can see Nashs full tweets with photos below:

Follow Marc on Twitter at @this_is_marc. Send any news, tips or corrections to us by clicking here.

See the original post:
Kevin Nash on How His Health Is After Knee Replacement & Stem Cell Therapy, Why He Retired - LordsofPain.net

Stem Cell Alopecia Treatment Market 2019 Globally Expected to Drive Growth through 2024 – ReportsPioneer

With a multi-correctional approach, MRInsights.biz presents an extensive analysis of the historical, current and future outlook of the global Stem Cell Alopecia Treatment market along with the factors responsible for such a growth. The study author has served a complete outline of the market in a crystal clear format through which only an unskilled individual but also a professional can easily hypothesize the market easily. Our highly dedicated professionals have included critical and accurate insights related to the industry.

The report enhances the readers experience by giving a basic overview of the market and its classification. We have considered 2019 as the base year, 2024 as the estimated year, and 2019-2024 as the stipulated timeframe. The report proposes the segmental study of the global Stem Cell Alopecia Treatment market where it divides the periphery of the industry into segments such as product type, applications of the market, regional market spaces, and more.

DOWNLOAD FREE SAMPLE REPORT: https://www.mrinsights.biz/report-detail/185248/request-sample

Stem Cell Alopecia Treatment Market Competitive Rivalry:

The report highlights company profiles of the leading player combined with the investment forecast, the recent technology trends, and future forecasts. In addition, the section covers key financial knowledge, current developments, strategies employed by the major players, and SWOT outline. Along with the rise in innovation, mergers and acquisition activities in the industry, the market opposition is continuously developing greater.

The leading manufacturers and suppliers of the in-market include: Company 1, Company 2, Company 3, Company 4, Company 5, .,

Major regions that play a vital role in Stem Cell Alopecia Treatment market are: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

The market can be segmented into product types as: Alopecia Areata, Alopecia Totalis, Alopecia Universalis

The market can be segmented into applications as: Hospitals, Clinic, Others

The report further highlights the factors hampering the development, leading companies, supply-demand chain, futuristic facts, economic strategies, government policies, and topological statistics. It has carefully discussed client-specific details such as enterprise gross margin, present industrial policies, market statistics, import-export details, and government regulations. Some of the key focuses of Stem Cell Alopecia Treatment market covered in the report includes key trends such as technology advancement, globalization, capacity in developed markets, market bifurcation, product production, and regulation & environmental concerns.

ACCESS FULL REPORT: https://www.mrinsights.biz/report/global-stem-cell-alopecia-treatment-market-2019-by-185248.html

Research Study Offers A Detail Analysis of This Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Read the rest here:
Stem Cell Alopecia Treatment Market 2019 Globally Expected to Drive Growth through 2024 - ReportsPioneer

Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference – GlobeNewswire

Press release

Gosselies, Belgium, 9 January 2020, 7 am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address highly unmet medical needs in orthopaedics and bone diseases, today announces that Chief Executive Officer, Dr. Miguel Forte, MD, PhD, will attend the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, 13-16 January 2020.

If you would like to meet with Dr. Miguel Forte from Bone Therapeutics at the conference, please contact investorrelations@bonetherapeutics.com.

The Company will also host, in collaboration with Arrowhead Business and Investment Decisions, LLC investor meetings in New York and Boston on 23 and 24 January.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis following the positive Phase IIb efficacy results in patients with knee osteoarthritis which showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) to start the pivotal Phase III program has been submitted to the regulatory authorities in Europe and the trial is expected to start in Q1 2020.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the strong Phase IIa efficacy and safety results for ALLOB, the Company plans to submit a CTA with the regulatory authorities before year-end 2019 to initiate a Phase IIb clinical trial with ALLOB in patients with difficult-to-heal fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at http://www.bonetherapeutics.com.

Contacts

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Consilium Strategic CommunicationsMarieke VermeerschTel: +44 (0) 20 3709 5701bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

See more here:
Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

The Region’s Health Leaders on What’s New and What the Next Decade Will Bring – Business West

Vision 2020

Few industries change as rapidly and as dramatically as the broad, multifaceted realm of healthcare. From oncologists use of cancer fingerprinting and gene therapy to facial transplants for accident victims; from cutting-edge protocols to save the lives of stroke and heart-surgery patients to a dizzying array of new treatments to improve vision the list is seemingly endless, making it impossible to paint a full picture of where healthcare has come in the past decade.

But we at BusinessWest wanted to try anyway and, at the same time, look ahead at what the next decade might bring. So, appropriately, here at the dawn of 2020, we invited a wide range of healthcare professionals to tell us what has been the most notable evolution in their field of practice in the past 10 years, and what they expect or hope will be the most significant development to come in the next decade.

The answers were candid, thoughtful, sometimes surprising, but mostly hopeful. Despite the many challenges healthcare faces in these times of advancing technology, growing cost concerns, and demographic shifts, the main thread is still innovation smart people working on solutions that help more people access better care. After all, healthcare is, at its core, about improving peoples lives, even when they seek it out during their direst moments.

Innovation and promise. Thats what we believe a new decade will bring to all corners of the healthcare world that is, if these leaders, and countless others like them, have anything to say about it.

Joanne Marqusee

President and CEO, Cooley Dickinson Health Care

Joanne Marqusee

The most significant recent development in healthcare administration has been a recognition of the role patients play in their own healthcare. Crossing the Quality Chasm: A New Health System for the 21st Century, published in 2001 by the Institute for Healthcare Improvement, called for a massive redesign of the American healthcare system. Specifically, it provided Six Aims for Improvement, five of which focused on safety, effectiveness, timeliness, efficiency, and equity. Not talked about as much, the sixth aim was to make healthcare patient-centered.

While we still have a ways to go to truly be patient-centered, we have witnessed a sea change in the past decade in this regard. Patients are increasingly active participants in their care, questioning their doctors and other providers to ensure that they understand their options, using electronic medical records to engage in their care, and speaking out about what they want from treatment or forgoing treatment at the end of life. The best healthcare providers both organizations and individuals embrace these changes, welcoming patients as more than recipients of care, but rather active partners in their own care and decision making.

My hope for the most significant development over the next decade has to do with providing universal healthcare coverage while controlling healthcare costs. While we almost have universal coverage in Massachusetts, too much of the nation does not. A hotly debated topic, universal healthcare has many benefits, including increasing access to preventive and routine medical care, improving health outcomes, and decreasing health inequalities.

Dr. Nicholas Jabbour

Chairman, Department of Surgery, Baystate Medical Center

Dr. Nicholas Jabbour

The most significant development in surgery over the past decade has been the move toward less invasive surgical approaches made possible through advanced technology. These approaches include robotic and minimally invasive surgery, including intraluminal surgery in areas such as gastroenterology, cardiology, and neurosurgery for exemple, the passage of an inflatable catheter along the channel inside of a blood vessel to enable the insertion of a heart valve instead of making a large opening in the chest. As a result, we have seen a big shift from inpatient to outpatient surgery with shorter hospital stays and improved post-op recovery.

In the next decade, we foresee these innovations in less invasive surgery will be enhanced by better computing and software integration. This interaction will include the merging of radiological and potentially pathological information which is currently available in a digital format with real-time visualization of anatomical structure during surgery. This will offer surgeons the opportunity to improve the accuracy and speed of a surgical procedure while minimizing the risks.

The next decade will also see major innovation in the area of transplantation with the development of tissues or whole organs through bio-engineering manipulation of animal or a patients own cells. The integration of this bio-engineering manipulation with currently available technology, such as 3D printing and 3D imaging, will provide patients with the needed tissue or organ including valves, bone grafts, hernia mesh, skin, livers, and kidneys in a timely manner. This development will revolutionize the field of transplantation and surgery in general.

Karin Jeffers

President & CEO, Clinical & Support Options Inc.

Karin Jeffers

Over the past 10 years, weve seen a growing adoption within the behavioral-health and medical fields of holistic treatment models. While the two disciplines were once treated as different animals, the entire health field is now moving to treat both the body and the mind together. The next 10 years are likely to bring these two fields even closer.

Today, youre seeing behavioral-health clinicians being hired into physical health practices. Likewise, physical health providers are cross-training to better understand behavioral issues. Whereas, a decade ago, a behavioral-health client might be assigned a therapist or a psychiatrist, they are now gaining access to more robust set of supports, including nursing, case management, recovery coaching, and peer support from those with lived experience. Government mandates and payment model changes are forcing outcomes-based integration, too. Pediatricians, for example, must now do behavioral-health screenings of all youth under 21. In the mental-health space, youre seeing clinicians ask about weight, exercise, and other physical factors.

Were seeing significant movement on both the state and federal levels to value outcomes over volume. Its reflected in the criteria set by the Excellence in Mental Health Act for certified community behavioral-health clinics, a designation CSO has earned, and in the work we have done with the Substance Abuse and Mental Health Services Administration. Our ability to tailor programs, like our grant-funded work at the Friends of the Homeless shelter in Springfield, has literally saved lives among those experiencing homelessness and co-occurring conditions, like substance-use disorders.

In the coming years, we hope to see integrated care models become even more mainstream. Things appear headed in the right direction, but government action establishing payment reform within the behavioral-health field needs to be taken and the integrated models need to be appropriately funded. Such changes would affirm overall health and wellness to include both physical and behavioral health.

Dr. Yannis Raftopoulos

Director, Holyoke Medical Center Weight Management Program

Dr. Yannis Raftopoulos

Weight management is a rapidly evolving field, and I am fortunate to be part of it. One of the most significant innovations this field has experienced in the last 10 years was the development of a new gastric balloon. Packaged in a small capsule and swallowed with water, the Elipse balloon provides satiety while requiring no procedure or anesthesia for its placement and removal. Together with its excellent safety profile, the Elipse balloon is the least invasive and yet effective weight-loss modality available today. Elipse is manufactured in Massachusetts by Allurion Technologies.

I had the opportunity to be an investigator in the European trial which led to the Elipse market approval in the European Union in 2016. Recently, Holyoke Medical Center was among 10 U.S. sites in which an FDA-regulated trial was conducted. The trial was completed successfully, and Allurion has submitted data requesting FDA approval to market Elipse in the U.S. The balloons use in Europe shows that patients can lose more than one-fifth of their initial weight.

A New England Journal of Medicine study reported that 107.7 million children and 603.7 million adults, among 195 countries, were obese in 2015. High body-mass index accounted for 4 million deaths and contributed to 120 million disability-adjusted life-years. Obesity is a chronic disease, and its management requires long-term guidance and close patient-physician communication. Successful collaborations between existing best practices with technology innovations that will allow delivery of effective weight-management care on a massive and global scale could be the most significant evolution in the field in the next 10 years.

Dr. Hong-Yiou Lin

Radiation Oncologist, Mercy Medical Center

Dr. Hong-Yiou Lin

The advent of new medical oncology drugs has improved control of microscopic and, to a lesser extent, macroscopic disease, allowing local treatments, such as surgery or radiotherapy, to increase survival. To cure cancer, we need to eliminate cancer cells where they started, as well as any microscopic cells traveling through the body. The idea of using immunotherapy to fight cancer has been around for decades, but bringing this idea to the clinic has been hampered by the cleverness of cancer cells knowing how to evade detection by our immune system. Recently FDA-approved immunotherapy either takes away that invisibility cloak or wakes up our dormant immune cells to start fighting cancer.

The biggest development in oncology in the next 10 years will be personalized precision medicine, which allows the oncology team to tailor treatment to each patients unique cancer biology and life circumstances. Meanwhile, improvements in cancer diagnosis will come from novel PET radiotracers and new MRI sequences that allow for more accurate staging and identification of the best site to biopsy. Pathologists will use novel tools such as genome sequencing to supplement traditional microscopy to subclassify the specific type of cancer within a certain diagnosis instead of grouping into broad categories.

Surgical, medical, and radiation oncologists can then use the above information to decide on the best sequencing between surgery, systemic therapy, and radiotherapy to minimize side effects and maximize cure. Medical oncologists will be able to offer more drugs that target new mutations, overcome drug resistance, increase specificity to a mutation, or better fine-tune immunotherapy, targeting only cancer cells by enlisting gene modification as well as natural killer cells. Radiation oncologists will have new radiomic and genomic tools to personalize the radiation dose and volume, and when to offer radiotherapy.

In short, over the next 10 years, cancer care will continue to move away from the traditional one-size-fits-all model toward a more personalized approach.

Dr. Jonathan Bayuk

Medical Director, Allergy & Immunology Associates of New England

Dr. Jonathan Bayuk

There have been incredible and exciting advances in allergy and immunology in the last two years. However, the unmet needs of allergic and autoimmune-disease-afflicted patients has grown dramatically in the last 20 years. In response to the increasing prevalence and acuity of allergic diseases and autoimmune diseases, the world has launched products to help address these very severe patients. These medications are indicated for many conditions and work very well. They are generally safe, but are very expensive. These medicines are different than traditional pharmaceutical drugs as they are not chemicals, but biologically derived medicines designed to augment or modify the immune response. As such, they are call biologic medications.

In the field of allergy and immunology, we can now dramatically treat and potentially cure many diseases that in the past were very challenging to manage. The biologic medicines that we have now treat asthma, eczema, allergic disease, and hives. The patient selection is based on severity of their condition, and these medicines are only for moderately to severely affected people. If, as a medical profession, we were to place as many people as possible on these therapies, the cost would be astronomical and not sustainable.

However, is it fair to deny any of these patients access to these treatments who truly need them? I would argue that choice is a very difficult one to make, and as physicians, our primary goal is healing at whatever cost. As a nation, we have a dilemma. Can we afford the medicines we have or not? It is unclear that any serious legislative body is willing to tackle that question. For now, the use of these medicines is changing lives dramatically, and it is an exciting time to be able to use these newer tools to help our patients live better lives.

Dr. David Momnie

Owner, Chicopee Eye Care

Dr. David Momnie

What are the most significant advancements in eye care in the last decade? It depends on whom you ask. Retinal ophthalmologists would probably say its the treatment of wet macular degeneration, a leading cause of blindness, with anti-VEGF injections. Cataract surgeons would most likely cite small-incision surgery and new lens implants that often leave patients with 20/20 vision. Glaucoma specialists might tell you its the development of MIGS, or minimally invasive glaucoma surgery. These operations to lower the pressure in the eye use miniature devices and significantly reduce the complication rate.

Primary-care optometrists and ophthalmologists would no doubt talk about the advances in optical coherence tomography, a remarkable instrument using light waves that gives cross-sectional pictures of the retina. The technique is painless and non-invasive and is becoming the gold standard in eye care because it has revolutionized the diagnosis and treatment of glaucoma and macular degeneration. For optometrists specializing in contact lenses, using newly designed scleral lenses to restore vision in people with a corneal disease called keratoconus has been a major development. There are many other specialists in eye care, including LASIK surgeons, that have seen remarkable changes in technology.

What will the next decade bring? Artificial intelligence (AI) is becoming more accurate for screening, diagnosing, and treating eye conditions. AI systems can increasingly distinguish normal from abnormal pictures of the retina. Where there is a shortage of ophthalmologists and optometrists, AI screenings combined with telemedicine, providing remote care using communications technology, may be able to find and treat more people who are falling between the cracks of our healthcare system. The term 20/20 is the most common designation in eye care, and the year 2020 will probably usher in another decade of remarkable developments in our field.

Teresa Grogan

Chief Information Officer, VertitechIT

Teresa Grogan

From the perspective of technology that enables healthcare, the biggest game changer of the last decade has been the iPhone and now, essentially any smartphone.

Steve Jobs introduced the first iPhone in 2007 (a little over a decade ago), and physicians embraced it quickly. It started as a simple tool for doctors (applications like the PDR, or Physicians Desk Reference) for looking up drug interactions. Today, its a portable EMR, a virtual visit facilitator, and a remote-monitoring device for many healthcare providers, as many patients have embraced and insisted on this technology to improve access to care. As the cost decreases and cellular bandwidth improves, the rapid growth of the IoMT (Internet of Medical Things) will place smartphones at the center of the next wave of healthcare technology breakthroughs.

Looking forward, Id like to see complete elimination of passwords to access electronic information. While there has been some movement toward this with tap and go badges and fingerprint readers, a single standard is needed that would work regardless of the software program used. I hope there are greater strides in the creation, deployment, and adoption of other biometric technologies, like iris, face, or voice recognition, so that a healthcare professional could walk into a patient room or into a hospital and the computer systems would know his or her identity in immediate and secure fashion. If access to the data needed by a healthcare provider were as easy as turning on a light switch, the improvements in quality of life and efficiency in work for that provider would translate to improved patient outcomes.

Dr. Aaron Kugelmass

Vice President and Medical Director, Heart and Vascular Program, Baystate Health

Dr. Aaron Kugelmass

We have seen many improvements in cardiovascular care over the last 10 years, but the development, approval for clinical use, and dissemination of transcutaneous aortic valve replacement (TAVR) stands out as the most dramatic. This new technique allows cardiologists and cardiac surgeons, working together, to replace the aortic valve without opening a patients chest or utilizing heart-lung bypass, which has been the standard for decades. This less invasive approach is typically performed under X-ray guidance and involves accessing a blood vessel in the leg and guiding a catheter to the heart.

The TAVR procedure was first approved for clinical use in November 2011. It was initially limited to very sick patients, who were not candidates for traditional surgery because of the risk it posed to them. TAVR allowed patients who otherwise could not receive life-saving valve surgery to have their valves replaced with improvement in longevity. With time and experience, the procedure was approved for lower-risk patients as well, and more recently has been approved for the majority of patients, including those with low operative risk. TAVR has been shown to be equivalent or safer than traditional aortic valve-replacement surgery, and is quickly becoming the procedure of choice for most patients who require an aortic valve replacement. Since the procedure typically does not require open-heart surgery, recovery time is much shorter, with some patients going home within a day or two.

In the next 10 years, we expect that similar less-invasive procedures with shorter recovery time will be developed for other heart-valve conditions in patients who otherwise could not receive therapy.

Beth Cardillo

Certified Dementia Practitioner and Executive Director, Armbrook Village

Beth Cardillo

During the last 10 years, neuroscientists have been researching the causes of Alzheimers disease. There has been much discussion about which comes first the amyloid plaque or the fibrillary tangles that develop in the brain, which are roadblocks to cognition, thus causing the difficulties with Alzheimers and other related dementia. That question has not been answered yet. Researchers were able to isolate the APOE gene, which is a mutant gene that is found in familial Alzheimers disease, helping us to better diagnose it. We have also better understood how diet, exercising both body and brain, and lifestyle contribute to the disease. Currently there are 101 types of dementia, with Alzheimers accounting for 75% of cases.

The next 10 years will result in more preventive actions. One major action will be to help people avoid developing type 2 diabetes, which may be labeled the next cause of Alzheimers (this type of Alzheimers is already being called type 3 diabetes). There has been a major link between sugar in the hippocampus and Alzheimers disease. Though there is no cure yet for Alzheimers, we are finding more information based on genetics, diet, and PET scans, which can show shrinkage in the brain.

Every year, researchers are more hopeful that a new drug will be developed to eradicate the disease. The last new drug from Biogen was looking hopeful in clinical trials, but that turned out to be not the case. Prevention continues to be at the forefront, as well as participating in clinical trials. More people who do not have dementia or mild cognitive impairment are desperately needed for clinical trials so comparisons of the brain can be made.

Ellen Furman

Director of Nursing, American International College

Ellen Furman

As in all healthcare, the one thing that can be ascertained is constant change. The same can be said in nursing education today. No longer is the instructor-led lecture method of teaching considered best practice in education, but rather the shift to using class time to apply learned concepts. One way this is done is through the flipped classroom. Using this educational modality, students study the concepts being taught preceding the class, followed by class time where students apply these concepts in an interactive activity, thereby developing students abilities to think critically, reason, and make healthcare judgements based upon the application of knowledge.

Another change in nursing education is an expanded focus away from pure inpatient (hospital-based) clinical education to outpatient (community-based) clinical education. While hospital-based education remains essential, the realization that most healthcare provided is in outpatient settings has broadened the clinical experiences required to prepare the graduate registered nurse for care provision.

Additionally, with healthcare as complex as it is, nursing students are being taught to be prepared for entry into practice. Education regarding the use of evidence-based practice, how to apply for the licensure examination, preparation to be successful on the National Certification Licensure Exam, nurse residency opportunities, interviewing techniques, transitioning from student nurse to registered nurse, etc. are all taught using a variety of educational modalities based upon the current best available evidence in nursing education.

As we forge ahead in healthcare, nurse educators will continue to evolve to meet healthcare needs through the education of nursing students so as to prepare them to provide care to meet the needs of those we serve well into the future.

James Haas

Co-owner, Orthotics & Prosthetics Labs Inc.

James Haas

Advances in prosthetic technology have clearly been the most significant development in my field over the past decade. From knees and feet that adapt to different walking speeds and terrains to hands that send sensations of touch to the brain, every aspect of patient care has changed and continues to change at a rapid pace.

Prosthetic feet, knees, and sockets have been greatly impacted. Once made from multi-durometer foams and wood, the prosthetic feet of today are made from carbon, fiberglass, and kevlar laminated with modified epoxy resins. They store energy and adjust to uneven terrain and hills. Microprocessor knees have on-board sensors that detect movement and timing and then adjust a fluid/air control cylinder accordingly. These knees not only make it safer for a person to walk, they also lower the amount of effort amputees must use, resulting in a more natural gait. Sockets once made from stiff materials are now incorporated with soothing gels and flexible adjustable systems that allow a patient to make their own adjustments to improve their comfort.

As for the next decade, I hope to see national insurance fairness. Devices typically last about three to five years. Some people make them last longer, but others, especially growing children, need replacements more often. Many private insurance plans have annual caps and lifetime limits on coverage for orthotics and prosthetics. The Amputee Coalition of America authored insurance-fairness legislation and has lobbied for its implementation for over a decade. This legislation has been ratified in 20 states, including Massachusetts. The Fairness Act requires all insurance policies within the state to provide coverage for prosthetics and orthotics equal to or better than the federal Medicare program and have no coverage caps and lifetime restrictions.

Dr. Lisa Emirzian

Co-owner, EMA Dental

Dr. Lisa Emirzian

The most significant development in the field of dentistry over the past decade has been the integration of digital technology into our daily practices. There are three components of digital dentistry: data acquisition, digital planning, and, finally, the manufacturing of the restoration to be created. Data acquisition today is accomplished with digital radiographs, paperless charting, intra-oral scanners, cone-beam 3D scanners, and video imaging. For the planning process, we now have the ability to merge the data with software that enables computer-aided design and digital smile design, allowing dentists to perform complex procedures, including guided surgical treatments and smile designs, with optimum results. Fabrication and execution of the final restorations can be done in the office or, more often, in laboratories with highly sophisticated digital milling machines, stereolithography, and 3D printing.

In the next decade, we will see data fusion to ultimately create the virtual patient. The next-generation digital workflow will merge intra-oral 3D data with 3D dynamic facial scans, allowing dentists to create 3D smile designs and engineer the dentofacial rehabilitation. The integration of scanners and software will expedite the delivery of teeth in a day. In addition, multi-functional intra-oral scanners will allow for early detection of carious lesions and determine risk levels for different patients.

Above and beyond this foreseeable future, artificial intelligence (AI) will be the next paradigm shift. Companies are already looking for big-data collection and deep machine learning to help the practitioner in their everyday chores of diagnosis and treatment. AI cloud-based design platforms will input data, and AI engines in the background will aid in all parts of dental treatment, including diagnosis, design, and fabrication of final restoration.

Let us not forget one thing: the future is all about us people utilizing technology to enhance the human connection between doctor and patient.

John Hunt

CEO, Encompass Health Rehabilitation Hospital of Western Massachusetts

John Hunt

A significant rehabilitation development from the past includes one that may surprise you. Time. A luxury we once knew, time meant patients could recover in a hospital longer after a surgery, an accident, or an illness. Nurses had more time to assess patients to know exactly what they needed. Insurance companies approved longer patient stays through lengthy consideration. Ten years ago, a stroke survivor could recover for two weeks in a hospital and then join us for a rehabilitation stay that would last several weeks.

Today, a three- to five-day stay in the referring hospital, followed by a two-week stay in rehabilitation, is the norm. We are seeing significant decreases in the age of stroke survivors as well as an increase in the number patients who survive with cognitive and physical disabilities. Yet, we also see medical breakthroughs, including the discovery of tissue plasminogen activator (TPA) nothing short of a miracle. TPA actually reverses the effects of an evolving stroke in patients when used early on, making recoveries easier.

With new advanced technologies being introduced every year, rehabilitation continues to progress at a rapid speed. Looking into the future, evidence-based research will continue to grow to help us make knowledgeable decisions that ultimately impact patient outcomes. Increased clinical expertise will lead to higher functional gains in shorter amounts of time. As a result, acute inpatient rehabilitation will impact the lives of patients like weve never seen before.

Dr. Susan Bankoski Chunyk

Doctor of Audiology, Hampden Hearing Center

Dr. Susan Bankoski Chunyk

The most common treatment for hearing loss is hearing aids. Although digital processing has been available in hearing aids since 1996, the past 10 years have offered great leaps in technology for people with hearing loss. Each generation of computer chip provides faster and smarter processing of sound. Artificial intelligence allows the hearing-aid chip to adjust automatically as the listening environment changes, control acoustic feedback, and provide the best speech signal possible. People enjoy the convenience of current hearing aids Bluetooth streaming, smartphone apps, and rechargeable batteries.

These features are the icing on the cake, but the real cake is preservation of the speech signal, even in challenging listening situations. Since the primary complaint of people with hearing loss is understanding in noise, new hearing-aid technology works toward improving speech understanding while reducing listening effort in all environments. This significantly improves the individuals quality of life.

The negative effects of untreated hearing loss on quality of life are well-documented. Recent research has also confirmed a connection between many chronic health conditions including diabetes, cardiovascular disease, kidney disease, balance disorders, depression, and early-onset dementia and hearing loss. This research shows that hearing loss is not just an inevitable consequence of aging, but a health concern that should be treated as early as possible. My hope for the future is that all healthcare providers will recognize the value of optimal hearing in their patients overall health and well-being and, just as they monitor and treat other chronic health conditions, they will recommend early diagnosis and treatment of hearing loss.

See the original post:
The Region's Health Leaders on What's New and What the Next Decade Will Bring - Business West

Endothelial Dysfunction Industry 2019-2025 Market Analysis by Size, Share, Growth, Regional, Manufactures, Application and Forecast Research Report -…

The Asia-Pacific Endothelial Dysfunction market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Endothelium dysfunction can be defined as partial or complete loss of balance between vasodilating and vasoconstricting substances produced by the endothelium.

Ask for Sample Copy of This Report @https://www.orianresearch.com/request-sample/875202.

The Global Endothelial Dysfunction Industry based on geographic classification is studied for industry analysis, size, share, growth, trends, segment, top company analysis, outlook, manufacturing cost structure, capacity, supplier and forecast to 2025. Along with the reports on the global aspect, these reports cater regional aspects as well as global for the organizations

Top Key Vendors:

Abbott LaboratoriesChugai Pharmaceutical Co. Ltd.Johnson & JohnsonGlucox Biotech ABStealth Peptides Inc

Rise in number of obese populations, reduced physical activities and diabetes leading to increase in chances of acquiring cardiovascular diseases will propel the market growth in the forecast period. Stringent regulation regarding the drug will hamper the market growth in the forecast period. Advances in recombinant and gene therapy are also favoring the growth of endothelial dysfunction drugs uptake and can be an opportunity area for new entrants in the market.

Based on application, the market is segmented into, hospital, clinics among others.

Based on diagnosis, the market is segmented into, coronary circulation, angiography of coronary artery.

Based on region the market is segmented into China, India, Japan, South Korea, Taiwan, Southeast Asia, and Australia.

Global Endothelial Dysfunction Industry is spread across 121 pages, profiling 05 companies and supported with tables and figures.

Inquire more or share a question if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/875202.

Key Benefits of the Report:* Global, Regional, Country, Learning Module, and Type Market Size and Forecast from 2014-2025-Provide attractive market segments and associated growth opportunities* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies* Identification of key companies that can influence this market on a global and regional scale* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies* Detailed insights on emerging regions, product & Learning Module, and competitive landscape with qualitative and quantitative information and facts

Target Audience:* Endothelial Dysfunction providers* Traders, Importer and Exporter* Raw material suppliers and distributors* Research and consulting firms* Government and research organizations* Associations and industry bodies.

Order a copy of Global Endothelial DysfunctionMarket Report 2019 @https://www.orianresearch.com/checkout/875202

TABLE OF CONTENT

Introduction

Methodology & Scope

Global Endothelial Dysfunction Market Overview

Asia-Pacific Endothelial Dysfunction Market by Diagnosis type

Asia-Pacific Endothelial Dysfunction Market by Application

Asia-Pacific Endothelial Dysfunction Market by Region

Competitive Landscape

Company Profiles

End of TOC

About UsOrian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

See the rest here:
Endothelial Dysfunction Industry 2019-2025 Market Analysis by Size, Share, Growth, Regional, Manufactures, Application and Forecast Research Report -...

Cell Harvesting Market is Expected to Reach USD 387.9 Million by 2025| Bertin, Tomtec, Terumo BCT, HynoDent AG, Avita Medical, Argos Technologies -…

The Global Cell Harvesting Market is expected to reach USD 387.9 Million by 2025, from USD 196.9 Million in 2017 growing at a CAGR of 8.9% during the forecast period of 2018 to 2025. Some of the major players operating in the global cell harvesting market are PerkinElmer Inc, Bertin, Tomtec, Terumo BCT, HynoDent AG, Avita Medical, Argos Technologies, SP Industries, Teleflex Incorporated, Arthrex, Inc, Thomas Scientific, Brand GMBH, Brandel, Cox Scientific, Connectorate, Scinomix, Adstec.

Global Cell Harvesting Market,By Type (Manual Cell Harvesters and Automated Cell Harvesters), By Application (Biopharmaceutical Application, Stem Cell Research and other Applications), By End Users (Hospitals, Ambulatory Centers, Clinics, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Request For Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cell-harvesting-market

Market Definition:Global Cell Harvesting Market

This market report defines the market trends and forecast the upcoming opportunities and threats of the cell harvesting market in the next 8 years. Cell harvesting is extracting the cells either from bone marrow and peripheral blood cells and culturing the cells in the culture dish containing nutrient media. Cell harvesting is used in the cell therapy as well as in gene therapy. University of California developed a cure for bubble baby disease for new born babies by using the cell harvesting in stem cells and gene therapy. Moreover, Asterias developed the stem cell therapy to regain the upper body motor function. University of California, Irvine developed the stem cell therapy to destroy the breast cancer cells.. Now a days cell harvesting is also used in the animal research and development. Cell Harvesting is also used in may research labs for in-Vitro testing. In September 2016, Terumo BCT collaborated with Cognate Bioservices for developing the immunotherapies and other related products like cell therapy products. These innovations in the cell harvesting market is notably attributing towards its increasing demand at the global pace. Further, its demand is likely to gain momentum over the forecast period.

Major Market Drivers and Restraints:

View Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-cell-harvesting-market

Market Segmentation:Global Cell Harvesting Market

The global cell harvesting market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cell harvesting market for global, Europe, North America, Asia Pacific and South America.

Research Methodology:Global Cell Harvesting Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaseRequest an Analyst Callor can drop down your inquiry.

Demand Side Primary Contributors: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others

To Buy Complete Report Click Here @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cell-harvesting-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [emailprotected]

See the original post:
Cell Harvesting Market is Expected to Reach USD 387.9 Million by 2025| Bertin, Tomtec, Terumo BCT, HynoDent AG, Avita Medical, Argos Technologies -...

MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair – BioSpace

Funding to Support Ongoing Advancement of siFi2, Lead Candidate from Companys First-of-its-Kind Platform for Precisely Controlling Core Cell Migration Mechanisms

New York, NY, January 7, 2020 MicroCures, a biopharmaceutical company developing novel therapeutics that harness the bodys innate regenerative mechanisms to accelerate tissue repair, today announced that it has been awarded a Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The two-year, $1.5 million award will support ongoing development of the companys lead product candidate, siFi2. siFi2, a small interfering RNA (siRNA) therapeutic that can be applied topically, is designed to enhance recovery after trauma. This Phase 2 grant continues the companys successful Phase 1 SBIR contract which demonstrated significantly improved repair of burn wounds following treatment with siFi2 in animal models.

MicroCures technology is based on foundational scientific research at Albert Einstein College of Medicine regarding the fundamental role that cell movement plays as a driver of the bodys innate capacity to repair tissue, nerves, and organs. The company has shown that complex and dynamic networks of microtubules within cells crucially control cell migration, and that this cell movement can be reliably modulated to achieve a range of therapeutic benefits. Based on these findings, the company has established a first-of-its-kind proprietary platform to create siRNA-based therapeutics capable of precisely controlling the speed and direction of cell movement by selectively silencing microtubule regulatory proteins (MRPs).

The company has developed a broad pipeline of therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. Unlike regenerative medicine approaches that rely upon engineered materials or systemic growth factor/stem cell therapeutics, MicroCures technology directs and enhances the bodys inherent healing processes through local, temporary modulation of cell motility. The companys lead drug candidate, siFi2, is a topical siRNA-based treatment designed to silence the activity of Fidgetin-Like 2 (FL2), a fundamental MRP, within an area of wounded tissue. In doing so, the therapy temporarily triggers accelerated movement of cells essential for repair into an injury area. Importantly, based on its topical administration, siFi2 can be applied early in the treatment process as a supplement to current standard of care.

We are grateful for NIHs continued support of our work through this multi-year Phase 2 SBIR grant. This non-dilutive financial support allows us to continue building a robust portfolio of preclinical data in animal models that demonstrate the therapeutic potential of siFi2 to significantly improve and accelerate healing of burn wounds, said David Sharp, Ph.D., co-founder and chief science officer of MicroCures. This funding will help advance our research as we work towards first-in-human clinical trial in 2020.

The initial Phase 1 SBIR grant from NIH funded preclinical research by MicroCures which demonstrated that treatment with siFi2 accelerated re-epithelization, improved collagen deposit and maturation, and improved quality of healing in a porcine full thickness burn model. Specific findings showed that following eight weeks of treatment, 39% of siFi2-treated wounds were closed as compared to only 11% for control subjects and 0% for placebo. Additionally, siFi2-treated subjects demonstrated a significantly improved rate of healing as measured by epithelial surface measurements as compared to placebo (p = 0.0106) and control (p = 0.0012).

About MicroCures

MicroCures develops biopharmaceuticals that harness innate cellular mechanisms within the body to accelerate and improve recovery after traumatic injury. MicroCures has developed a first-of-its-kind therapeutic platform that precisely controls the rate and direction of cell migration, offering the potential to deliver powerful therapeutic benefits for a variety of large and underserved medical applications.

MicroCures has developed a broad pipeline of novel therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. The companys lead therapeutic candidate, siFi2, targets excisional wound healing, a multi-billion dollar market inadequately served by current treatments. Additional applications for the companys cell migration accelerator technology include dermal burn repair, corneal burn repair, cavernous nerve regeneration, spinal cord regeneration, and cardiac tissue repair. Cell migration decelerator applications include combatting cancer metastases and fibrosis. The company protects its unique platform and proprietary therapeutic programs with a robust intellectual property portfolio including eight issued or allowed patents, as well as eight pending patent applications.

For more information please visit: http://www.microcures.com

Disclaimer: The SBIR Grant (2R44AR070696-02A1) is supported by the NIHs National Institute of Arthritis and Musculoskeletal and Skin Diseases. The content of this press release is solely the responsibility of MicroCures and does not necessarily represent the official views of the NIH.

Read the original:
MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair - BioSpace